homepage-top-section

The company has randomized the first patient of the mid-stage trial which will assess the efficacy and safety of Blautix in patients having IBS with constipation (IBS-C) and/or

Filgotinib, an investigational and selective JAK1 inhibitor, has achieved its primary efficacy endpoint in adults with moderately to severely active AS in the phase 2 Tortuga study. AS

Under the agreement, Aurobindo will purchase Sandoz US dermatology business and generic US oral solids portfolio. As part of the deal, Aurobindo will acquire manufacturing facilities in Wilson

The approval was based on data from Reflect study, which showed Lenvima’s treatment effect on overall survival (OS) by statistical confirmation of non-inferiority and also improved progression-free survival

Under the deal, the partnership will carry out research and development activities for the advancement of mRNA-based flu vaccines. BioNTech co-founder and CEO Dr Ugur Sahin said: “Today’s

Based in Vienna, Austria, Haplogen is a biotechnology company focused on developing therapeutic substances for the treatment and prevention of infection by the common cold virus. The multi-year

Ankylosing spondylitis is a painful and progressive type of arthritis, in which some or all of the joints and bones of the spine fuse together. The disease is

Onpattro is claimed to be the first-of-its-kind RNAi therapeutic and only FDA-approved treatment for this indication. Earlier, Onpattro secured breakthrough therapy and orphan drug designations from the FDA.

Millendo is engaged in the development of novel treatments for orphan endocrine diseases. The combined company will further advance Millendo’s pipeline of transformative treatments for orphan endocrine diseases.